A 57-year-old female with recurrent AML underwent a T cell-depleted (TCD) bone marrow (BM) plus TCD and CD34-selected peripheral blood stem cell (PBSC) transplant. Eleven weeks post transplantation, the patient developed acute graft-versus-host disease (GVHD) manifested by rash and elevated liver enzymes. Concurrently, the patient presented with a bleeding diathesis and a left forearm hematoma due to the development of a spontaneous factor VIII inhibitor. She was treated with human recombinant factor VIII and intravenous methylprednisolone. Subsequently she was managed with a prednisone taper leading to resolution of the GVHD, as well as the spontaneous factor VIII inhibitor. Bone marrow transplant-related spontaneous factor VIII inhibitor has previously been reported in association with one patient with chronic GVHD. To our knowledge this is the first report of spontaneous factor VIII inhibitor associated with acute GVHD. Bone Marrow Transplantation (2001) 27, 887-889. Keywords: bone marrow transplantation; peripheral blood stem cell transplant; graft-versus-host disease; spontaneous factor VIII inhibitor Graft-versus-host disease (GVHD) is a common complication of conventional bone marrow transplant (BMT).
Acute GVHD occurs within the first 3 months after transplantation and is a pathologically different entity from chronic GVHD. The latter develops later in the post-transplant course, and is frequently observed in patients previously afflicted with acute GVHD. Acute GVHD is mediated, in part, by donor T cell reactivity to host alloantigens, and thus occurs less frequently in patients who receive T cell-depleted grafts. 2 The common manifestations of acute GVHD, which include rash, gastrointestinal symptoms, simple liver enzyme abnormalities to frank liver failure, and immunodeficiency are also different from those of chronic GVHD, which are of an autoimmune type (xerostomia, scleroderma-type skin changes, etc). We describe a patient treated for AML with a combined TCD BM plus TCD and CD34-selected PBSC transplant who developed a factor VIII inhibitor and bleeding diathesis in the setting of acute GVHD. To our knowledge there are no previously reported cases of spontaneous factor VIII inhibitor developing in association with acute GVHD.
Case report
A 57-year-old female initially presented to our institution in 1995 with a diagnosis of AML. Induction and consolidation therapy consisted of cytarabine and idarubicin followed by cytarabine, mitoxantrone, and etoposide which resulted in a prolonged remission. The patient was followed without further therapy for approximately 2 years but became progressively anemic and bone marrow evaluations demonstrated myelodysplasia. Eventually the decision was made to proceed to bone marrow transplant using a 6/6 HLA matched sibling donor. Coagulation studies from both the patient and the donor were consistently normal prior to transplant, and no family history of autoimmune disease was reported by either the patient or the donor.
The conditioning regimen for transplant included hyperfractionated total body irradiation to a total of 1375 cGy, followed by thiotepa and cyclophosphamide. The patient received a graft consisting of soybean-agglutinated erosette (SBA-E) TCD BM plus SBA-E − CD34 + PBSCs. The total CD34 + cell dose was 4.73 × 10 6 /kg, the total CD3+ cell dose was 2.1 × 10 4 /kg. Anti-thymocyte globulin and a short course of methylprednisolone were given to facilitate engraftment. No additional agents were given for GVHD prophylaxis. The post-transplant hospitalization was complicated by neutropenic fever and cytomegalovirus (CMV) viremia, which were successfully treated with antibiotics and ganciclovir (DHPG). The patient was discharged on day +29 without GVHD and with normal coagulation studies.
Approximately 11 weeks post transplantation, the patient developed a macular rash that was histologically consistent with acute GVHD. Further work-up revealed elevated AST, ALT, alkaline phosphatase, and lactate dehydrogenase levels. One week later the patient's PT was normal, but the PTT was prolonged to 81.5 s (normal, 26.4-34.6 s). Mixing study revealed 50/50 mix = PTT of 50.9 s (normal 33.4). Subsequent coagulation studies, including one-stage factor VIII and factor VIII inhibitor assays, 3 detected a factor VIII inhibitor of 90 Bethesda units. Due to the risk of hemorrhage, a liver biopsy could not be performed, and since the skin GVHD did not resolve with topical steroid therapy, prednisone at 1 mg/kg/day was begun. One week later, the patient presented to the hospital with a painful, enlarging hematoma in the left antecubital fossa after a routine venipuncture. Concern about a possible compartment syndrome prompted admission to the hospital. The first dose of recombinant human factor VIII, 70 U/kg, was given and intravenous methylprednisolone at 2 mg/kg/day was initiated. A second dose of 70 U/kg of factor VIII was administered on the second hospital day. Over the following 5 days, the hematoma began to resolve. With reduction of the PTT, improvement of the liver enzyme abnormalities and rash, the patient was discharged on a prednisone taper. The liver enzyme studies continued to improve and the PTT trended back to normal (Figure 1 ). Four weeks after discharge, the hematoma had resolved, there were no further bleeding complications, and the acute GVHD had resolved. Unfortunately, a follow-up factor VIII inhibitor level was not obtained.
Discussion
Factor VIII inhibitor is an antibody to factor VIII most commonly seen in patients with hemophilia A, who develop antibodies to exogenously administered factor VIII. Such inhibitors can be seen as a rare, spontaneous, autoimmune phenomenon in nonhemophilic patients. The incidence of spontaneous inhibitors is estimated to be 0.2-1 per million per year in the general population. 4 While most cases remain idiopathic, autoimmune disorders, malignancy, diseases of the skin and respiratory tract, medications, and the postpartum period are all associated with their development. [5] [6] [7] [8] Furthermore, medications including penicillin-like antibiotics, have been associated with the development of spontaneous antibodies to factor VIII. 8 Our patient was treated with ticarcillin at the time of the transplant for a neutropenic fever. However, we are unaware of any reported cases of factor VIII inhibitor related to treatment with this antibiotic. Interestingly, cytomegalovirus (CMV) infection has also been associated. In fact, in one recent published series of nonhemophilic patients with factor VIII inhibitor, two of 10 reported cases were associated with CMV infection. 7 While factor VIII inhibitor has been reported in one patient after BMT as a manifestation of chronic GVHD, to our knowledge there are no previously reported cases of factor VIII inhibitor associated with acute GVHD. 9 Acute GVHD, mediated by donor T cells, does not characteristically involve antibody-mediated pathology. A B cellmediated pathology in the early post-transplant period is difficult to explain, but is not without precedent. Greeno et al 10 recently reported a 3% incidence of newly acquired lupus anticoagulant developing within the first 2 months after BMT. While the pathogenesis of such antibody formation remains to be elucidated, several possible explanations can be proposed. These include: incidental transfusion of donor immunoglobulins, antibodies produced by donor B cells, or antibody production by surviving host B cells.
In our patient, both the donor as well as the recipient had normal coagulation studies prior to transplantation, indicating that this was not a pre-existing condition. To what extent, if any, either previous antibiotic treatment, or the patient's CMV viremia played a role in the development of her factor VIII inhibitor is unknown. However, ticarcillin treatment was completed 10 weeks prior to presentation, and assays for CMV antigenemia and culture were negative just before and during the time of maximum levels of factor VIII inhibitor in this patient.
There are no standard treatment regimens to manage spontaneous factor VIII inhibitors. Historically, treatment of acute bleeding has been managed with infusion of human or porcine-derived factor VIII concentrates, [5] [6] [7] infusion of activated prothrombin complex concentrates, activated factor VII, or plasma-derived DDAVP. More recently, the development of recombinant human factor VIII has eliminated the risk of virus transmission associated with these blood products.
Immunosuppressive medications, such as corticosteroids, azathioprine, cyclophosphamide, and cyclosporin A, [5] [6] [7] are the mainstay of therapy directed at the eradication of factor VIII autoantibodies. Removal of factor VIII inhibitor with plasmapheresis has also been reported. 7 Our patient presented with a limb threatening hematoma which required rapid hemostatic control with infusion of concentrated factor VIII. After stabilization of the hematoma, additional treatment was managed conservatively with corticosteroids. With this regimen we were able to treat the acute GVHD and resolve the bleeding diathesis. A similar rapid response to corticosteroid treatment was reported by Seidler et al, 9 who managed a spontaneous factor VIII inhibitor associated with chronic GVHD.
In summary, we report the development of a spontaneous factor VIII inhibitor associated with symptoms of acute GVHD of the skin and liver, in a patient less than 3 months after allogeneic BMT. Successful treatment included human recombinant factor VIII infusion and corticosteroids. We conclude that spontaneous factor VIII inhibitor is a possible complication in the setting of both acute and chronic GVHD. The diagnosis of antibody-mediated dis-orders needs to be considered in BMT patients presenting with unexplained bleeding complications, or other autoimmune-type symptoms even early in the post-transplant course.
